Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial.
Saved in:
| Title: | Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial. |
|---|---|
| Authors: | Cree BA; Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, USA., Selmaj KW; Center for Neurology, Łódź, Poland and Collegium Medicum, Department of Neurology, University of Warmia and Mazury in Olsztyn, Olsztyn, Poland., Steinman L; Department of Neurology and Neurological Sciences, Beckman Center for Molecular Medicine, Stanford University Medical Center, Stanford, CA, USA., Comi G; Vita-Salute San Raffaele University and Casa di Cura del Policlinico, Milan, Italy., Bar-Or A; Center for Neuroinflammation and Experimental Therapeutics, and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Arnold DL; NeuroRx Research and Montréal Neurological Institute, McGill University, Montréal, QC, Canada., Hartung HP; Department of Neurology, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany/Brain and Mind Centre, The University of Sydney, Sydney, Australia/Department of Neurology, Medical University of Vienna, Vienna, Austria/Department of Neurology, Palacky University Olomouc, Olomouc, Czech Republic., Montalbán X; Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona, Spain., Havrdová EK; Department of Neurology and Center for Clinical Neuroscience, First Medical Faculty, Charles University, Prague, Czech Republic., Sheffield JK; Bristol Myers Squibb, Princeton, NJ, USA., Minton N; Bristol Myers Squibb, Princeton, NJ, USA., Cheng CY; Bristol Myers Squibb, Princeton, NJ, USA., Silva D; Bristol Myers Squibb, Princeton, NJ, USA., Kappos L; Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Head, Spine and Neuromedicine, Clinical Research, Biomedicine, and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland., Cohen JA; Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, OH, USA. |
| Source: | Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2022 Oct; Vol. 28 (12), pp. 1944-1962. Date of Electronic Publication: 2022 Jun 28. |
| Publication Type: | Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: SAGE Publications Country of Publication: England NLM ID: 9509185 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1477-0970 (Electronic) Linking ISSN: 13524585 NLM ISO Abbreviation: Mult Scler Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1477-0970 |
|---|---|
| DOI: | 10.1177/13524585221102584 |
